100 Migraine Drugs, A to Z: duloxetine

November 27, 2018

Duloxetine (Cymbalta) is an antidepressant in the family of serotonin-norepinephrine reuptake inhibitors (SNRIs). Unlike the selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac), escitalopram (Lexapro) and other, SNRIs not only treat depression and anxiety, but also relieve pain and prevent migraine headaches.

Duloxetine is specifically approved by the FDA for the treatment of major depression, generalized anxiety, musculoskeletal pain, such as low back pain and pain due to osteoarthritis, as well as pain of fibromyalgia and diabetic peripheral neuropathy.

Duloxetine is not officially approved for the treatment of migraine headaches, but it is been widely for this indication. There are no large controlled trials, but several small studies show that it may be effective even for chronic migraines with medication overuse. Most studies employed a dose of 60 mg, but one study suggested that high doses of the drug (120 mg) may be more effective for the prevention of episodic migraine headaches.

Considering that duloxetine is proven to relieve pain of different types, it is very likely that it is effective for the prevention of migraines as well. It is particularly a good choice in patients with comorbid anxiety and depression and these conditions are 2-3 times more likely to occur in migraine sufferers.

Potential side effects include insomnia, drowsiness, fatigue, nausea, dizziness, suicidal thoughts in depressed children and young adults, and other

Sudden discontinuation of duloxetine can cause withdrawal symptoms, which may consist of one or more of the following symptoms: dizziness, headache, nausea, diarrhea, paresthesia (pins-and-needles), irritability, vomiting, insomnia, anxiety, sweating, and fatigue. These can be avoided by a very gradual reduction in the dose. On occasion, when the dose is down to the smallest size capsule of 20 mg, stopping it can cause withdrawal symptoms. In such cases I advise the patient to open the capsule and to discard ever increasing amounts of the drug for a period of a week or two.

Written by
Alexander Mauskop, MD
Continue reading
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe